Drug Trial Radar · NCT06922448
Study of BLU-808 in Allergic Rhinoconjunctivitis
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Apr 14, 2025
Primary completion
Sep 8, 2025
Study completion Sep 8, 2025
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic rhinoconjunctivitis (ARC). Participants will undergo eligibility assessments that include exposure to ragweed pollen in an allergen exposure chamber (AEC).
Conditions
- Allergic Rhinoconjunctivitis
Interventions
BLU-808Drug
BLU-808 tablets
PlaceboDrug
Placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 through Day 56
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Red Maple Trials
Ottawa, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.